证券代码：603222 证券简称：济民健康 公告编号：2025-049 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 关于以集中竞价交易方式回购股份的进展公告 重要内容提示： | 回购方案首次披露日 | 2025/3/29 | | --- | --- | | 回购方案实施期限 | 待董事会审议通过后 个月 12 | | 预计回购金额 | 10,000万元~20,000万元 | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | □用于转换公司可转债 □为维护公司价值及股东权益 | | 累计已回购股数 | 200.55万股 | | 累计已回购股数占总股本比例 | 0.38% | | 累计已回购金额 | 1,208.90万元 | | 实际回购价格区间 | 5.87元/股~6.13元/股 | 一、回购股份的基本情况 济民健康管理股份有限公司(以下简称"公司")于 2025 年 3 月 28 日召开第 五届董事会第十七次会议，审议通过了《关于以集中竞价交易方式回购股份方案 的议案》，同意公司使用自有资金及金融 ...

Core Points - The company approved a share repurchase plan with a maximum price of 10 CNY per share and a total fund amount of 100 million to 200 million CNY, valid for up to 12 months from the board's approval date [1] - As of September 30, 2025, the company has repurchased a total of 2.0055 million shares, accounting for 0.3819% of the total share capital, with a maximum purchase price of 6.13 CNY per share and a minimum price of 5.87 CNY per share, totaling 12.089 million CNY spent (excluding transaction fees) [1] - No repurchase was executed in September 2025, and the company will repurchase shares as per regulations and disclose information in a timely manner [1]

Core Viewpoint - Jimin Health (603222.SH) is transitioning from a focus on large-volume infusion, medical devices, and healthcare services to becoming an innovative pharmaceutical company, marked by the acceptance of a clinical trial application for DB006 on September 26, 2025 [1]. Group 1: Company Transition - Jimin Health's subsidiary, Boao International Hospital, received a clinical trial acceptance notice for DB006, a oncolytic adenovirus injection, indicating the company's first step towards becoming an innovative drug enterprise [1]. - The registration classification of DB006 is as a Class 1 therapeutic biological product, signifying a significant shift in Jimin Health's business model since its establishment in 1996 [1]. Group 2: Market Context - In 2020, China reported 4.57 million new cancer cases and 3 million cancer deaths, with high incidence and mortality rates for liver, stomach, esophageal, and cervical cancers [1]. - Breast cancer has the highest incidence rate, followed by lung and colorectal cancers, with lung cancer remaining the leading cause of cancer-related deaths [1]. Group 3: Oncolytic Virus Therapy - Oncolytic virus therapy is recognized as a promising new type of cancer treatment, characterized by high efficiency in killing tumor cells, specificity, safety, low side effects, and cost-effectiveness [2]. - Currently, five oncolytic virus drugs have been approved globally, with approximately seven oncolytic virus drugs in clinical trials in China, most in Phase I/II [2]. Group 4: Product Details - DB006 is designed for the treatment of advanced malignant solid tumors, utilizing genetic engineering to enhance tumor-specific replication and selectively infect tumor cells [2]. - In preclinical models, DB006 demonstrated over 70% tumor suppression in colon cancer models and complete tumor remission in non-small cell lung cancer models [2]. Group 5: Financial Performance - In the first half of 2025, Jimin Health reported total revenue of 366 million yuan, a decrease of 21.3% year-on-year, with a net loss attributable to shareholders of 52.7 million yuan [3]. - The company attributed its losses to reduced revenue and profit from medical devices due to U.S. tariff policies and inventory write-downs related to specific products [3].

Core Insights - The medical device sector experienced a slight increase of 0.39% on September 29, with Tianzhihang leading the gains [1] - The Shanghai Composite Index closed at 3862.53, up 0.9%, while the Shenzhen Component Index closed at 13479.43, up 2.05% [1] Medical Device Sector Performance - Tianzhihang (688277) saw a closing price of 18.47, with a rise of 7.70% and a trading volume of 172,400 shares, amounting to a transaction value of 315 million yuan [1] - Jimin Health (603222) closed at 11.30, up 5.51%, with a trading volume of 494,600 shares and a transaction value of 556 million yuan [1] - Dongxing Medical (301290) closed at 29.32, increasing by 4.86%, with a trading volume of 99,500 shares and a transaction value of 29.67 million yuan [1] - Other notable performers included Sainuo Medical (688108) with a 4.82% increase and a closing price of 27.83, and Tianchen Medical (688013) with a 3.89% increase, closing at 59.52 [1] Capital Flow Analysis - The medical device sector saw a net inflow of 85.63 million yuan from institutional investors, while retail investors contributed a net inflow of 46.52 million yuan [2] - However, speculative funds experienced a net outflow of 132 million yuan [2] Individual Stock Capital Flow - Sainuo Medical (688108) had a net inflow of 111 million yuan from institutional investors, but a net outflow of 68.66 million yuan from speculative funds [3] - Mairui Medical (300760) also saw a significant net inflow of 107 million yuan from institutional investors, with a net outflow of 76.49 million yuan from speculative funds [3] - Jimin Health (603222) had a net inflow of 53.49 million yuan from institutional investors, while speculative funds saw a net outflow of 43.40 million yuan [3]

申请人：海南济民博鳌国际医院有限公司、广州达博生物制品有限公司 受理号：CXSL2500840 证券代码：603222 证券简称：济民健康 公告编号：2025-048 济民健康管理股份有限公司 关于控股子公司药品临床试验申请取得受理通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 博鳌国际医院 DB006 溶瘤腺病毒注射液已正式获得国家药品监督管理局 药品审评中心受理 I 期临床研究申请。根据我国药品注册相关的法律法规要求， 临床试验申请获得受理后，自受理之日起 60 日内，未收到国家药品监督管理局 药品审评中心否定或质疑意见，方能按照已提交的方案开展临床试验，期间结果 具有一定的不确定性。生物药品具有高科技、高风险、高附加值的特点。药品的 前期研发以及产品从研制、临床试验、上市审批到产业化生产的周期长、环节多， 容易受多种不确定因素的影响。公司将按照有关规定，对项目进展情况及时履行 信息披露义务，敬请广大投资者谨慎决策，注意防范投资风险。 济民健康管理股份有限公司（以下简称"公司"）控股子公司 ...

Core Viewpoint - Jimin Health (603222) announced that its subsidiary, Hainan Jimin Boao International Hospital Co., Ltd., received the acceptance notice for the clinical trial application of DB006 on September 26, 2025, from the National Medical Products Administration's Center for Drug Evaluation (CDE) [1] Company Summary - The DB006 oncolytic adenovirus injection is a gene therapy drug aimed at treating advanced malignant solid tumors [1]

Group 1 - The A-share market saw a collective rise in the three major indices, with the Shanghai Composite Index increasing by 0.9%, the Shenzhen Component Index by 2.05%, and the ChiNext Index by 2.74% as of September 29 [1] - The Medical Device ETF (562600) experienced a late surge, rising by 0.53%, with its top holdings, Tianzhihang-U and Jimin Health, gaining 7.7% and 5.51% respectively [1] - The Medical Device ETF attracted 5.65 million yuan in capital over the past five days, indicating strong investor interest [1] Group 2 - The 92nd China International Medical Equipment Fair (CMEF) was held from September 26 to 29 in Guangzhou, covering nearly 160,000 square meters and attracting around 3,000 companies from nearly 20 countries and regions, with expectations of over 120,000 professional visitors [1] - CMEF serves as a global barometer for the medical industry, showcasing the latest achievements and trends in the medical device sector, with significant participation from regions like Guangdong, Jiangsu, and Zhejiang, as well as international exhibitors from Germany, the USA, and Japan [1] Group 3 - Huazhong Securities noted that high-value consumables have moved past the impact of centralized procurement, with leading companies in various segments increasing their market share and gaining recognition from high-level hospitals and doctors [2] - The Medical Device ETF (562600) tracks the CSI All-Share Medical Device Index, selecting 100 representative listed companies in core medical fields, with the medical device sector accounting for 89.34% of the index [2] - As of September 17, the top ten holdings of the Medical Device ETF included Mindray Medical and United Imaging Healthcare, which together accounted for 22.9% of the ETF [2]

Core Viewpoint - Jimin Health (603222.SH) announced that its subsidiary, Hainan Jimin Boao International Hospital, received a clinical trial acceptance notice from the National Medical Products Administration for the DB006 oncolytic adenovirus injection, indicating progress in its gene therapy development for advanced malignant solid tumors [1] Group 1 - The Boao International Hospital's DB006 oncolytic adenovirus injection is designed for the treatment of advanced malignant solid tumors [1] - The product utilizes genetic engineering to modify oncolytic viruses for selective infection of tumor cells and enhanced tumor-specific replication capabilities [1] - The therapy incorporates multiple anti-tumor and immune-regulating genes to target and kill tumors through various pathways [1]

Core Viewpoint - Jimin Health (603222.SH) announced that its subsidiary, Hainan Jimin Boao International Hospital, received a clinical trial acceptance notice from the National Medical Products Administration (NMPA) for the DB006 oncolytic adenovirus injection, aimed at treating advanced malignant solid tumors [1] Group 1: Company Developments - The Boao International Hospital's DB006 oncolytic adenovirus injection is a gene therapy drug designed for advanced malignant solid tumors [1] - The product utilizes genetic engineering to modify oncolytic viruses for selective infection of tumor cells and enhanced tumor-specific replication capabilities [1] - The drug incorporates multiple anti-tumor and immune-regulating genes to target and kill tumors through various mechanisms [1]

Market Review - The CITIC Pharmaceutical Index decreased by 1.98%, underperforming the CSI 300 Index by 1.54 percentage points, ranking 22nd among 30 CITIC first-level industries [7] - The top ten stocks by increase this week included Xiangrikui, Aopu Mai, and Xinlitai, with increases of 57.86%, 23.89%, and 15.81% respectively [7][37] - The top ten stocks by decrease included Borui Pharmaceutical and Jimin Health, with decreases of 38.36% and 19.65% respectively [7][37] Overall View and Investment Themes - The pharmaceutical sector is currently undervalued, with public funds (excluding pharmaceutical funds) having low allocation to the sector. The company maintains an optimistic outlook for the growth of the pharmaceutical industry in 2025, expecting diverse investment opportunities [12] - The innovative drug sector is transitioning from quantity to quality, focusing on differentiated and internationalized pipelines. Companies that can deliver profitable products are expected to be favored [12] - In the medical device sector, there is a noticeable recovery in bidding volumes for imaging equipment, and home medical devices are benefiting from subsidy policies. The company suggests focusing on key players in these areas [12] - The life sciences service sector is expected to see a rebound in overseas investment and domestic demand, with a focus on CXO and life science services as a growth driver [12] - The pharmaceutical industry is anticipated to enter a new growth cycle, particularly in the specialty raw materials sector, which is expected to benefit from cost improvements and low valuations [12] Industry and Individual Stock Events - The Chinese traditional medicine sector is expected to see growth driven by basic drug reforms and national enterprise reforms, with a focus on companies like Kunming Pharmaceutical Group and Kangyuan Pharmaceutical [10][31] - The medical service sector is expected to improve due to anti-corruption measures and centralized procurement, enhancing the competitiveness of private medical institutions [13][26] - The blood products sector is projected to grow significantly during the 14th Five-Year Plan period, with increased approval for plasma stations and expanding product offerings [13] - The medical device market is experiencing a shift towards domestic alternatives, particularly in high-value consumables and imaging equipment, with significant growth expected in 2024 and beyond [20][21] 2025Q3 Pharmaceutical Performance Outlook - Expected revenue growth rates for various companies in Q3 2025 range from 0% to over 60%, with notable mentions including Bai Pu Sai Si and Kanglong Huacheng [14] - The innovative drug sector is expected to see significant contributions from companies like Betta Pharmaceuticals and Hengrui Medicine, with growth rates projected between 10% and 30% [14] Investment Recommendations - The company recommends focusing on the pharmaceutical retail sector, particularly in light of the accelerating trend of prescription outflow and the optimization of competitive dynamics [25] - In the medical device sector, attention is drawn to companies benefiting from the recovery in bidding for imaging equipment and the growth of home medical devices [20] - The life sciences service sector is highlighted for its potential recovery and growth opportunities, particularly in overseas markets [24]